Fundraising FoxAduro Biotech
Unicorn exit · $3.5Bacquired by Chinook TherapeuticsBerkeley, US · Founded 2011 · Delaware corporation · 4 known investors
Find your way into Aduro Biotech
Sign up to see every warm intro you have to Aduro Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aduro Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Chinook Therapeutics October 2020 · $3.5B (Novartis acquired Chinook Therapeutics (the merged company) for $3.5 billion in 2023) · source ↗
Aduro Biotech was a Berkeley, CA clinical-stage biopharmaceutical company developing cancer immunotherapies, including STING-pathway agonists and Listeria-based vaccine platforms derived from UC Berkeley research.
Founders & leadership
Board
Investors · 4
How we know: Foresite Capital's portfolio page · funding news · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$92M disclosed across 2 rounds · 2014
▶$51.4MraisedJan 2015 · 28 investors · BiotechnologyRule 506(b)
- Frank McCormickDirector
- Gerald David ChanDirector
- Thomas DubenskyExecutive Officer
- Dirk G. BrockstedtExecutive Officer
- Ross HaghighatDirector
- William GreenmanDirector
- Stephanie O'BrienDirector
- Stephen IsaacsExecutive Officer, Director
- Jennifer LewExecutive Officer
- Gregory W. SchaferExecutive Officer
- Offering amount
- $51.4M
- Amount sold
- $51.4M
- Sales commissions
- $2.4M
- Placement agents
- Leerink Partners LLC
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$40.6MraisedJun 2014 · 25 investors · BiotechnologyRule 506(b)
- Stephanie O'BrienDirector
- Frank McCormickDirector
- Jennifer LewExecutive Officer
- Stephen IsaacsExecutive Officer, Director
- Gregory SchaferExecutive Officer
- Gerald David ChanDirector
- William GreenmanDirector
- Ross HaghighatDirector
- Offering amount
- $40.6M
- Amount sold
- $40.6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aduro Biotech do?
- Aduro Biotech was a Berkeley, CA clinical-stage biopharmaceutical company developing cancer immunotherapies, including STING-pathway agonists and Listeria-based vaccine platforms derived from UC Berkeley research.
- Who are Aduro Biotech's investors?
- Aduro Biotech's investors include Foresite Capital, ACCELERATOR LIFE SCIENCE PARTNERS, Franklin Templeton, OrbiMed.
- How much funding has Aduro Biotech raised?
- Aduro Biotech has disclosed $92M raised across 2 rounds.
- Who acquired Aduro Biotech?
- Aduro Biotech was acquired by Chinook Therapeutics.
- Where is Aduro Biotech headquartered?
- Aduro Biotech is headquartered in Berkeley, US.